Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Cancer

Dr. Norman Sharpless Sworn in as Director of the National Cancer Institute

Dr. Norman “Ned” Sharpless

Bethesda, MD, October 19, 2017 — Norman E. “Ned” Sharpless, M.D., took the oath of office October 17 to become the 15th director of the National Cancer Institute (NCI), part of the National Institutes of Health. H

Dr. Sharpless succeeds Harold E. Varmus, M.D., who stepped down as director in March 2015. Douglas R. Lowy, M.D., has been NCI’s acting director since April 2015.

“It is an honor to welcome Dr. Sharpless to the Department of Health and Human Services and the National Institutes of Health,” said Acting Health and Human Services Secretary Eric D. Hargan. Continue reading

American Cancer Society Report: Breast Cancer Death Rates Down 39 Percent Since 1989

Atlanta, GA, October 9, 2017 — A new report from the American Cancer Society finds that death rates from breast cancer in the United States have dropped 39% between 1989 and 2015.

This translates to 322,600 deaths avoided during those 26 years. African-American women still have higher breast cancer death rates than white women nationally.

The findings are published in Breast Cancer Facts & Figures 2017-2018 and in Breast Cancer Statistics, 2017 in CA: A Cancer Journal for Clinicians. Continue reading

PhRMA ‘Pipeline’ Report: 74 Percent of Medicines in Development Have Potential to Be First-in-Class Treatments

Washington, DC, September 26, 2017 — Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a new report by The Analysis Group, Inc. commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies. Continue reading

Sens. Menendez and Booker, Reps. Gottheimer and Pascrell Announce $363,583 Grant for Hackensack University Medical Center

Washington, DC, September 8, 2017 — Senators Bob Menendez and Cory Booker and Congressmen Bill Pascrell (NJ-8) and Josh Gottheimer (NJ-5) announced on September 7 that Hackensack University Medical Center in collaboration with the Stevens Institute of Technology will be receiving $363,583 in federal funds for cancer treatment research from the U.S. Department of Health and Human Services’ National Cancer Institute.

“Thanks to Hackensack UMC’s John Theurer Cancer Center, North Jersey is a key player in the battle against cancer. I’m hopeful that their path-breaking research will one day overcome multiple myeloma cells,” said Congressman Josh Gottheimer (NJ-5). Continue reading

FDA Approves First Gene Therapy to U.S.; Commissioner Gottlieb Says ‘A New Frontier in Medical Innovation’

Washington, DC, September 1, 2017 — The Food and Drug Administration (FDA) issued a historic action on August 30 making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases.

The FDA approved Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL).

FDA Commissioner Scott Gottlieb, M.D., said, “We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer.” Continue reading

Rutgers Cancer Institute Research Dr. Jennifer Tsui Receives $729K American Cancer Society Grant

Dr. Jennifer Tsui

New Brunswick, NJ, August 30, 2017 — Jennifer Tsui, PhD, a researcher at Rutgers Cancer Institute of New Jersey, has been awarded a $729,000 Mentored Research Scholar Grant in Applied and Clinical Research from the American Cancer Society to further explore health care delivery and care transitions for underserved cancer patients.

The award supports investigators who are in the early stages of their career in becoming independent researchers as either clinician scientists or cancer control and prevention investigators.

Despite evidence that vulnerable populations often receive poor quality care, few studies have focused on understanding the underlying health care processes that contribute to suboptimal cancer care or poor transitions between primary care and oncology care. Continue reading

Rutgers Cancer Institute Reports Favorable Safety Profile Seen in Immunotherapy Drug in Aggressive Form of Lung Cancer

Dr. Janice M. Mehnert

New Brunswick, NJ, August 18, 2017 — The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and “promising durable clinical activity” in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease.

That is according to data from a phase 1b clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and colleagues at centers around the world. The work appears in the current online edition of the Journal of Clinical Oncology (doi: 10.1200/JCO.2017.72.5069).

Janice M. Mehnert, MD, director of the Phase 1/Investigational Therapeutics Program at Rutgers Cancer Institute, and senior director on the work said, “Immunotherapy drugs put the body’s natural defenses bak to work by targeting the PD-L1 protein and PD-1 receptor and blocking their ability to prevent T cells from destroying cancer cells.” Continue reading

U.S. Senate Passes Bill to Improve Cancer Drugs for Children

Washington, DC, August 7, 2017 — Ledyard King reports in USA Today that, until now, drug companies have been free to decide whether to pursue treatments for pediatric cancers as part of their work on adult cancers.

They won’t have much choice going forward.

The Senate on August 3 overwhelmingly passed legislation requiring the pharmaceutical industry to expend more resources on treatment for childhood cancers. Continue reading

Rutgers Cancer Institute of New Jersey Investigators Receive $450K in Fellowship Grants

New Brunswick, NJ, July 27, 2017 — Rutgers Cancer Institute of New Jersey investigators have received $450,000 in funding to support research projects in immunotherapy and basic science research that could impact pancreatic, breast and other cancers.

The Pre- and Post-Doctoral Fellowship Grants were awarded by the New Jersey Commission on Cancer Research (NJCCR).

Eileen White, Ph.D., Rutgers Cancer Institute Deputy Director, Chief Scientific Officer and Associate Director for Basic Science, said, “As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute is dedicated to treatment, prevention, education and research.” Continue reading

VP Joe Biden and Dr. Jill Biden Launch Biden Cancer Initiative; Aims to Make Progress in Cancer Prevention, Detection, Treatment, Care

Dr. Jill Biden and Joe Biden

New York, NY, June 23, 2017 — President Joe Biden and Dr. Jill Biden on June 26 launched the Biden Cancer Initiative, their new venture to continue the fight to make progress in cancer prevention, detection, treatment, and care.

The launch event was highlighted by Vice President and Dr. Biden joining members of the Biden Cancer Initiative Board of Directors for a conversation about the mission of the Initiative, the issues it will address, and the promise of what they hope to accomplish together.

The Biden Cancer Initiative will develop and drive implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research and care, and to reduce disparities in cancer outcomes. Continue reading